EDITING OUT CARDIOVASCULAR RISK: A NARRATIVE REVIEW OF GENE-EDITING APPROACHES TO PCSK9
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6188Keywords:
PCSK9, CRISPR Base Editing, Gene Editing, Epigenetic Silencing, LDL Cholesterol, Cardiovascular DiseaseAbstract
Background: PCSK9 is a circulating protease that regulates plasma low-density lipoprotein (LDL) cholesterol levels. It binds to the LDL receptor on the surface of hepatocytes and directs the receptor toward intracellular degradation, so that greater PCSK9 activity leaves fewer LDL receptors available to clear LDL-C from the bloodstream. PCSK9 was established as a drug target largely through human genetics: naturally occurring loss-of-function variants are associated with lifelong low LDL-C and a markedly reduced risk of atherosclerotic cardiovascular disease with no apparent adverse consequences, whereas gain-of-function variants cause a severe, early onset form of familial hypercholesterolemia. Pharmacological PCSK9 inhibitors, monoclonal antibodies, and small interfering RNA (siRNAs) are currently in clinical use; however, all require repeated, lifelong administration.
Aim: This review argues that PCSK9 gene editing has progressed from a theoretical concept to an emerging therapeutic class, with three distinct technical strategies currently under active development. We compared CRISPR-Cas9 nuclease knockout, base editing, and epigenetic silencing with established antibody and siRNA classes, focusing on efficacy, durability, and safety.
Materials and Methods: A search of relevant research databases and a hand search of selected journals were conducted to identify eligible papers.
Results: Several programs based in the United States and China have demonstrated that a single dose of a gene-editing agent can lower PCSK9 and LDL-C levels in humans and animal models. Nuclease-mediated knockout and base editing produced the largest reductions, whereas epigenetic silencing produced a smaller but reversible effect. The principal safety signal identified to date was attributed to the lipid-nanoparticle delivery vehicle, rather than the editing mechanism itself.
Conclusions: Early clinical and preclinical evidence supports the feasibility of PCSK9 gene editing. The remaining gaps are long-term safety data, direct evidence of reduced cardiovascular events rather than biomarker changes alone, and a strategy for equitable access and pricing.
References
Hobbs, H. H., Cohen, J. C., & Horton, J. D. (2024). PCSK9: From nature's loss to patient's gain. Circulation, 149(3), 171–173. https://doi.org/10.1161/CIRCULATIONAHA.123.064498
Lee, R. G., Mazzola, A. M., Braun, M. C., Platt, C., Vafai, S. B., Kathiresan, S., Rohde, E., Bellinger, A. M., & Khera, A. V. (2023). Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models. Circulation, 147(3), 242–253. https://doi.org/10.1161/CIRCULATIONAHA.122.062132
Musunuru, K., Chadwick, A. C., Mizoguchi, T., Garcia, S. P., DeNizio, J. E., Reiss, C. W., Wang, K., Iyer, S., Dutta, C., Clendaniel, V., Amaonye, M., Beach, A., Berth, K., Biswas, S., Braun, M. C., Chen, H. M., Colace, T. V., Ganey, J. D., Gangopadhyay, S. A., Garrity, R., … Kathiresan, S. (2021). In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature, 593(7859), 429–434. https://doi.org/10.1038/s41586-021-03534-y
Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., Kastelein, J. J. P., & ORION-10 and ORION-11 Investigators (2020). Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. The New England journal of medicine, 382(16), 1507–1519. https://doi.org/10.1056/NEJMoa1912387
Sabatine M. S. (2019). PCSK9 inhibitors: Clinical evidence and implementation. nature reviews. Cardiology, 16(3), 155–165. https://doi.org/10.1038/s41569-018-0107-8
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., Sever, P. S., Pedersen, T. R., & FOURIER Steering Committee and Investigators (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. The New England journal of medicine, 376(18), 1713–1722. https://doi.org/10.1056/NEJMoa1615664
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J. F., Tricoci, P., … ODYSSEY OUTCOMES Committees and Investigators (2018). Alirocumab and cardiovascular outcomes after acute coronary syndrome. The New England journal of medicine, 379(22), 2097–2107. https://doi.org/10.1056/NEJMoa1801174
Tsai, H. H., Kao, H. J., Kuo, M. W., Lin, C. H., Chang, C. M., Chen, Y. Y., Chen, H. H., Kwok, P. Y., Yu, A. L., & Yu, J. (2023). Whole genomic analysis reveals atypical non-homologous off-target large structural variants induced by CRISPR-Cas9-mediated genome editing. Nature communications, 14(1), 5183. https://doi.org/10.1038/s41467-023-40901-x
Hooper, A. J., Tang, X. L., & Burnett, J. R. (2024). VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce ldl-cholesterol. Expert opinion on investigational drugs, 33(8), 753–756. https://doi.org/10.1080/13543784.2024.2369747
Vafai, S. B., Täubel, J., Ashdown, T., Patel, R. S., Diamondali, S., Cegla, J., Soran, H., Bashir, B., Abitbol, A., Gaudet, D., Lauzière, A., Brunham, L. R., Newby, D. E., Nicholls, S. J., Scott, R. S., Kerr, J., Tardif, J. C., Lunken, C., Humphries, S. E., Karsten, V., … Kathiresan, S. (2026). In vivo base editing of PCSK9 with VERVE-102 for hypercholesterolemia. the new england journal of medicine, 10.1056/NEJMoa2601283. advance online publication https://doi.org/10.1056/NEJMoa2601283
Bajaj, A., & Rader, D. J. (2026). Base editing and silencing of PCSK9 shows clinical promise in humans. nature reviews. Cardiology, 23(7), 447–448. https://doi.org/10.1038/s41569-026-01297-5
Bharti, A., & Mudge, J. (2025). Therapeutic applications of CRISPR-Cas9 gene editing. Frontiers in genome editing, 7, 1724291. https://doi.org/10.3389/fgeed.2025.1724291
Lopes, R., & Prasad, M. K. (2024). Beyond the promise: Evaluating and mitigating off-target effects in CRISPR gene editing for safer therapeutics. Frontiers in bioengineering and biotechnology, 11, 1339189. https://doi.org/10.3389/fbioe.2023.1339189
Lazzarotto, C. R., Katta, V., Li, Y., Manquen, G., Wood, R. K., Chyr, J., Urbina, E., Matsubara, A., Lee, G., Wu, X., De Ravin, S. S., & Tsai, S. Q. (2026). Sensitive and unbiased genome-wide profiling of base-editor-induced off-target activity using CHANGE-seq-BE. nature biotechnology, 10.1038/s41587-025-02948-7. advance online publication https://doi.org/10.1038/s41587-025-02948-7
Wan, P., Tang, S., Lin, D., Lu, Y., Long, M., Xiao, L., Jiang, Y., Liao, J., Ma, X., Liu, Y., Yu, W., Ott, M., Wang, Z. J., Wu, Y., Yang, T., & Xia, Q. (2026). In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: A phase 1 trial. Nature medicine, 32(3), 1045–1051. https://doi.org/10.1038/s41591-026-04254-4
Ren, Z., Zhou, J., Yang, D., Guo, Y., Zhang, J., Xu, J., & Chen, Y. E. (2026). Gene editing therapies targeting lipid metabolism for cardiovascular disease: Tools, delivery strategies, and clinical progress. Cells, 15(2), 134. https://doi.org/10.3390/cells15020134
Chinese Clinical Trial Registry. (2024). A multicenter, open, single-arm, exploratory clinical study of ART002 in the treatment of heterozygous familial hypercholesterolemia. ID: ChiCTR2400093099. https://www.chictr.org.cn/showprojEN.html?proj=243932
Chinese Clinical Trial Registry. (2025). A Clinical Exploratory Study of YOLT-101 in the Treatment of Heterozygous Familial Hypercholesterolemia (HeFH) or Atherosclerotic Cardiovascular Disease (ASCVD)
ID: ChiCTR2500112984. https://www.chictr.org.cn/showprojEN.html?proj=290854
CRISPR Medicine News. (2025, February 26). News: The latest updates from the gene-editing clinical trials (February 2025). https://crisprmedicinenews.com/news/the-latest-updates-from-the-gene-editing-clinical-trials-february-2025/
CRISPR Therapeutics AG. (2026). Form 8-K (update including CTX310) U.S. securities and exchange commission. https://www.sec.gov/Archives/edgar/data/0001674416/000119312526204147/crsp-ex99_1.htm
HCPLive. (2024, April 2). Verve Therapeutics halts enrollment of Heart-1 PCSK9 gene therapy trial. https://www.hcplive.com/view/verve-therapeutics-halts-enrollment-of-heart-1-pcsk9-gene-therapy-trial
Innovative Genomics Institute. (2026, April 21). CRISPR clinical trials: A 2026 update. https://innovativegenomics.org/news/crispr-clinical-trials-2026/
Palmgren, G. (2026, March 25). Scribe Therapeutics positions epigenetic CRISPR for durable LDL-C reduction. CRISPR Medicine News. https://crisprmedicinenews.com/news/scribe-therapeutics-positions-epigenetic-crispr-for-durable-ldl-c-reduction/
Scribe Therapeutics. (2026, May). Scribe Therapeutics presents late-breaking preclinical data supporting STX-1150, a clinical-stage epigenetic silencing therapy designed to achieve years of LDL-C lowering after a single dose [Press release]. BusinessWire. https://www.businesswire.com/news/home/20260528472123/en/
Scribe Therapeutics. (2026, May). Scribe Therapeutics achieves regulatory clearance to initiate first-in-human clinical study of STX-1150 for LDL-C reduction [Press release]. BioSpace. https://www.biospace.com/press-releases/scribe-therapeutics-achieves-regulatory-clearance-to-initiate-first-in-human-clinical-study-of-stx-1150-for-ldl-c-reduction
tctmd.com. (2025, July 28). Topline data point to promise for VERVE-102 gene-editing therapy. https://www.tctmd.com/news/topline-data-point-promise-verve-102-gene-editing-therapy
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Piotr Bahyrycz, Karolina Markusiewicz, Magdalena Pyzik, Kinga Ziółkowska, Patryk Piotrowski, Alicja Włodarczyk, Aleksandra Jabłońska, Katarzyna Wites, Piotr Wites, Hubert Łagosz
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
